An agreement has been reached between Halozyme Therapeutics and Chugai Pharmaceutical where the latter paid a $25 million payment upfront to use the Enhanze enzyme technology for subcutaneous delivery of the desired molecule. The Chugai collaboration deal with Halozyme is worth up to $160 million in development, to be paid by Chugai Pharmaceutical which is a subsidiary of Roche.
The Chugai deal for Enhanze technology consists of many variables like regulatory and sales-based objectives, and royalty bonuses. These variables allow Chuagi to access the right to investigate the utilization of the recombinant human hyaluronidase PH20 enzyme with one of its medications up-and-comers. Chugai is yet to share the subtleties of how it intends to utilize the Enhanze technology licensing pact.
Reports about the arrangement come soon after another Halozyme associate, Argenx, announced promising Phase 3 information on a subcutaneous preparation created utilizing Enhanze. Argenx plans to petition for FDA endorsement before 2022 ends.
One of the core issues present in the Japanese pharmaceutical market is that despite the manufacturing market producing 20% of drugs used in the U.S, there are no efficient sales channels present there to distribute products at better rates. Therefore, this Chugai collaboration deal with Halozyme is expected to go a long way.
That pitch has reverberated with drug manufacturers. Chugai is Halozyme’s twelfth worldwide joint effort and permit accomplice for the Enhanze innovation. Altogether, this Chuagi deal for Enhanze technology cover the utilization of the innovation with more than 60 remedial targets. Five marketed items, including Johnson and Johnson’s Darzalex Faspro, utilize the innovation.
Halozyme markets Enhanze as a method for conquering the restrictions of administering drugs under the skin, in this way empowering more medication designers to change from intravenous to subcutaneous conveyance.
The chief executive officer of Halozyme Helen Torley commented “Our twelfth collaboration demonstrates the continued strong interest in providing patients with the option to receive treatment through a subcutaneous injection. This new collaboration further expands the number of Wave 5 potential launch programs, which we project will extend the revenue duration of our Enhanze franchise.”
Halozyme has doubled its revenue to $62.6 million by the end of 2021, owing to great sales uptake of Johnsons & Johnsons drug Darzalex and Roche’s Phesgo. These strong sales for Halozyme would continue well into 2022 with increased demand for Darzalex, numerous expansions, and introduction into new regions.
In 2021, Halozyme signed an agreement with ViiV Healthcare for the development of a subcutaneous preparation of its ultra-long-acting medication for the treatment of HIV. ViiV Healthcare is a joint venture of Pfizer and GSK for the development of HIV medication.
Halozyme will receive a payment of $40 million on the spot and an additional $175 million on completion of milestones from Pfizer and GSK.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
